Global biosimilars leader Sandoz has had its Marketing Authorization Application for its biosimilar to Amgen's (Nasdaq: AMGN) EU-licensed Neulasta (pegfilgrastim) accepted by the European Medicines Agency.
Neulasta is a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) and Sandoz, a Novartis (NOVN: VX) company, is seeking approval for the same indication as the reference product.
Richard Francis, Division Head and chief executive said: "Securing five major regulatory file acceptances in five months demonstrates substantial progress on our long-term biosimilars investment strategy. Further advancing our biosimilars pipeline is an important priority for us this year and we'll continue to invest significantly in bringing our pipeline to patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze